JP2010529958A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529958A5
JP2010529958A5 JP2010510812A JP2010510812A JP2010529958A5 JP 2010529958 A5 JP2010529958 A5 JP 2010529958A5 JP 2010510812 A JP2010510812 A JP 2010510812A JP 2010510812 A JP2010510812 A JP 2010510812A JP 2010529958 A5 JP2010529958 A5 JP 2010529958A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
group
disease
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010510812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529958A (ja
JP5671678B2 (ja
Filing date
Publication date
Priority claimed from EP07109652A external-priority patent/EP2027889A1/en
Application filed filed Critical
Publication of JP2010529958A publication Critical patent/JP2010529958A/ja
Publication of JP2010529958A5 publication Critical patent/JP2010529958A5/ja
Application granted granted Critical
Publication of JP5671678B2 publication Critical patent/JP5671678B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010510812A 2007-06-05 2008-06-05 ニューロン生存因子およびその使用 Active JP5671678B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07109652A EP2027889A1 (en) 2007-06-05 2007-06-05 New neuronal viability factor and use thereof
EP07109652.3 2007-06-05
PCT/EP2008/057031 WO2008148860A1 (en) 2007-06-05 2008-06-05 New neuronal viability factor and use thereof

Publications (3)

Publication Number Publication Date
JP2010529958A JP2010529958A (ja) 2010-09-02
JP2010529958A5 true JP2010529958A5 (enExample) 2011-07-21
JP5671678B2 JP5671678B2 (ja) 2015-02-18

Family

ID=38573348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010510812A Active JP5671678B2 (ja) 2007-06-05 2008-06-05 ニューロン生存因子およびその使用

Country Status (5)

Country Link
US (5) US9575075B2 (enExample)
EP (2) EP2027889A1 (enExample)
JP (1) JP5671678B2 (enExample)
ES (1) ES2623464T3 (enExample)
WO (1) WO2008148860A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
WO2009146183A1 (en) 2008-04-15 2009-12-03 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
CN110777124A (zh) 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
US9265786B1 (en) * 2012-03-30 2016-02-23 University Of Wyoming Method for reducing protein misfolding and accumulation in Huntington'S disease cells
JP6684343B2 (ja) * 2015-05-21 2020-04-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子の相乗組み合わせ及びその使用
KR20260085174A (ko) 2016-10-11 2026-06-08 파마 싱크, 엘엘씨 짧은 형태의 간상체 유래 원추체 생존능 인자와 친수성 펩타이드 사이의 융합 단백질
WO2018134168A1 (en) 2017-01-17 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors
KR102763312B1 (ko) 2017-10-20 2025-02-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
WO2019122403A1 (en) 2017-12-22 2019-06-27 Sparingvision Constructs comprising neuronal viability factors and uses thereof
ES3034370T3 (en) 2021-04-20 2025-08-18 Inst Nat Sante Rech Med Compositions and methods for treating retinal degenerative disorders
EP4366757A1 (en) * 2021-07-07 2024-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
KR20250115381A (ko) 2022-10-20 2025-07-30 스페어링비젼 망막 변성 질환 치료를 위한 조성물 및 방법
CN121285568A (zh) 2023-03-30 2026-01-06 制药五有限责任公司 编码视杆细胞源性视锥细胞活力因子和人IgK信号序列的载体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
FR2870241B1 (fr) * 2004-05-13 2015-02-27 Novartis Ag Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
JP5710265B2 (ja) * 2007-12-06 2015-04-30 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 網膜変性疾患の治療のための栄養因子
JP5748223B2 (ja) * 2008-09-10 2015-07-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子およびその使用
CN110777124A (zh) * 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
JP6684343B2 (ja) * 2015-05-21 2020-04-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子の相乗組み合わせ及びその使用
KR102763312B1 (ko) * 2017-10-20 2025-02-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
WO2019122403A1 (en) * 2017-12-22 2019-06-27 Sparingvision Constructs comprising neuronal viability factors and uses thereof

Similar Documents

Publication Publication Date Title
Fang et al. Adaptations to a subterranean environment and longevity revealed by the analysis of mole rat genomes
AU2024201282A1 (en) Compositions and methods for treating autoimmune diseases and cancers
RS64769B1 (sr) Varijante adeno-asociranih virusa i postupci upotrebe
IL268417B2 (en) Methods for cell-type specific profiling to identify drug targets
Xu et al. The soil emergence-related transcription factor PIF3 controls root penetration by interacting with the receptor kinase FER
US20210172017A1 (en) Methods of in vivo evaluation of gene function
US20220235102A1 (en) Specific nuclear-anchored independent labeling system
JP2017501697A (ja) サルモネラ菌の非コードｒｎａおよびその同定と使用
CN110760511B (zh) 一种用于治疗杜氏肌营养不良症的gRNA、表达载体、CRISPR-Cas9系统
Wu et al. Transcriptome analysis of different sizes of 3‐mercaptopropionic acid‐modified cadmium telluride quantum dot‐induced toxic effects reveals immune response in rat hippocampus
US20250154498A1 (en) Reagents for subcellular delivery of cargo to target cells
CN113711046A (zh) 用于揭示与Tau聚集相关的基因脆弱性的CRISPR/Cas脱落筛选平台
Lucibelli et al. Extending the toolkit for beauty: Differential co-expression of DROOPING LEAF-like and class B MADS-Box genes during Phalaenopsis flower development
CN115867678A (zh) 鉴定和表征指环病毒的方法及其用途
WO2023143150A1 (zh) 新型Cas酶和系统以及应用
US20060003959A1 (en) Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same
Brimacombe et al. Cloning and embryonic expression patterns of the chicken CELF family
Çakır et al. De novo transcriptome assembly and comparative analysis elucidate complicated mechanism regulating Astragalus chrysochlorus response to selenium stimuli
Tian et al. Comparative genomics provides insights into chromosomal evolution and immunological adaptation in horseshoe bats
CN108779495A (zh) 调节bckdh的方法
CN109134633A (zh) 抗稻瘟病蛋白和基因、分离的核酸及其应用
JP2016534752A (ja) 酸化ストレス、およびｄｎａに対する損傷によって引き起こされる疾患を処置するための、ｇｓｅ２４．２に由来するペプチド
US20240060963A1 (en) Compositions for detecting secretion and methods of use
CN1914336B (zh) 犬骨关节炎相关基因及相关的方法和组合物
US20130023643A1 (en) Nuclear localization signal peptides derived from vp2 protein of chicken anemia virus and uses of said peptides